PTCT logo

PTCT
PTC Therapeutics Inc

4,286
Mkt Cap
$6B
Volume
1.5M
52W High
$87.50
52W Low
$35.95
PE Ratio
9.36
PTCT Fundamentals
Price
$72.43
Prev Close
$71.70
Open
$73.35
50D MA
$68.47
Beta
1.19
Avg. Volume
1.21M
EPS (Annual)
$7.78
P/B
-28.74
Rev/Employee
$1.75M
$5,161.47
Loading...
Loading...
News
all
press releases
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Moderate Buy" by Brokerages
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has received an average recommendation of "Moderate Buy" from the sixteen ratings firms that are presently covering the company, MarketBeat.com...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire WARREN, N.J., April 17...
PR Newswire·2d ago
News Placeholder
State of Alaska Department of Revenue Increases Holdings in PTC Therapeutics, Inc. $PTCT
State of Alaska Department of Revenue lifted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 952.6% during the 4th quarter, according to its most recent filing with...
MarketBeat·3d ago
News Placeholder
Yousif Capital Management LLC Buys Shares of 22,228 PTC Therapeutics, Inc. $PTCT
Yousif Capital Management LLC bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·5d ago
News Placeholder
Burney Co. Takes Position in PTC Therapeutics, Inc. $PTCT
Burney Co. bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The...
MarketBeat·6d ago
News Placeholder
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Upgraded by Raymond James Financial
Raymond James Financial upgraded PTC Therapeutics to a "moderate buy" rating in a research report on Thursday...
MarketBeat·9d ago
News Placeholder
PTC Therapeutics (NASDAQ:PTCT) Now Covered by Analysts at Raymond James Financial
Raymond James Financial initiated coverage on shares of PTC Therapeutics in a research note on Friday. They set an "outperform" rating and a $108.00 price target on the stock...
MarketBeat·10d ago
News Placeholder
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,265 Shares
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Elliott Boulding sold 2,265 shares of PTC Therapeutics stock in a transaction on Monday, April 6th. The stock was sold at an average...
MarketBeat·11d ago
News Placeholder
PTC Therapeutics (NASDAQ:PTCT) EVP Sells $56,363.71 in Stock
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) EVP Lee Scott Golden sold 829 shares of PTC Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an...
MarketBeat·13d ago
News Placeholder
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) EVP Sells 829 Shares of Stock
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) EVP Lee Scott Golden sold 829 shares of the company's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price...
MarketBeat·13d ago
<
1
2
...
>

Latest PTCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.